Canadian regulator approves Albrioza to launch innovative approach to ALS

• Facebook
• Twitter
• Reddit
• Tumblr
• LinkedIn
• Pinterest
• RSS Feed
• Link

Canadian regulator approves Albrioza to launch innovative approach to ALS

• FDA Investigates T-Cell Malignancy Risk in CAR-T Cell Therapy
• WHO Requests More Information from China on Pediatric Clustered Pneumonia
• First Chinese PD-1 Cancer Drug 30 Times More Expensive in U.S. than in China
• Cardiovascular Diseases Linked to COVID-19 Infections
• What is the difference between dopamine and dobutamine?
• How long can the patient live after heart stent surgery?

Canadian regulator approves Albrioza to launch innovative approach to ALS.

On June 13, Amylyx Pharmaceuticals announced  that Canadian regulators have granted conditional marketing approval for Albrioza (sodium phenylbutyrate and taurine diol oral fixed-dose formulation) for the treatment of amyotrophic lateral sclerosis (ALS).

This is the first time this innovative therapy has received regulatory approval worldwide.

Speaking of ALS, readers may have heard of the “Ice Bucket Challenge,” a fundraiser that once swept social media and brought attention to ALS (aka ALS).

Famous physicist Professor Hawking once fought bravely against ALS for a long time.

The motor neurons in the brain and spine of people with the disease continue to die, resulting in muscle weakness and paralysis, ranging from the inability to walk to the inability to speak, swallow, and breathe. Amylyx reports that nearly half of ALS patients die within 2 years of diagnosis.

Although ALS was discovered more than 150 years ago, its pathogenesis is still not fully elucidated, with genetic mutations associated with about 10% of patients, and environmental factors are believed to play an important role.

Studies have shown that multiple signaling pathways ultimately lead to dysfunction of the endoplasmic reticulum and mitochondria. Mitochondria are the “energy centers” of cells, while the endoplasmic reticulum is the “factory” for the production of various proteins.

Disorders of these two organelles can lead to protein folding errors, abnormal energy metabolism and other problems, resulting in the death of nerve cells.

▲ Multiple pathways lead to dysfunction of the endoplasmic reticulum and mitochondria, resulting in neuronal death (Image source: Amylyx official website)

Amylyx’s Albrioza (previously known as AMX0035) originated from the thinking of two college students, Joshua Cohen and Mr. Justin Klee, in their college dorms. The idea is to delay nerve cell death by improving the health of mitochondria and endoplasmic reticulum inside cells.

Albrioza contains two ingredients – sodium phenylbutrate (PB) and taurursodiol (TURSO). Sodium phenylbutyrate is a small molecule protein chaperone that reduces the unfolded protein response (UPC) and prevents UPC-induced cell death. Taurine diol is a Bax protein inhibitor.

They can improve the health of mitochondria and endoplasmic reticulum within cells. When Amylyx first started, the two co-founders were only 21 and 22 years old.

▲The mechanism of action of Albrioza (AMX0035) (Image source: Amylyx official website)

The approval of Albrioza was based on a Phase 2 clinical trial called CENTAUR involving 137 ALS patients.

Results of the trial showed a mean improvement of 2.32 points in patients treated with Albrioza, which was assessed using a scale called ALSFRS-R.

The findings have been published in the prestigious medical journal “New England Journal of Medicine”.

▲Albrioza significantly improved the ALSFRS-R score (Image source: Amylyx’s official website)

The results, published in Muscle & Nerve, showed that patients who received Albrioza also experienced longer median survival.

▲Albrioza prolongs the survival of ALS patients (Image source: Amylyx official website)

One of the conditions for marketing approval by Canadian regulators is that Amylyx needs to conduct a confirmatory clinical trial to further verify the efficacy of Albrioza in patients with ALS.

At present, the company has launched a global Phase 3 clinical trial called PHOENIX, which is expected to recruit about 600 ALS patients.

The primary endpoints of the trial were patient survival and functional assessment. Amylyx expects top-line results from this clinical trial in 2024.

“I have been involved in caring for ALS patients for over 30 years. We have made important breakthroughs in scientific research and made great strides in drug development. The approval of Albrioza is a testimony to these advances.” Montreal Neurological Institute Dr. Angela Genge, director of the ALS Global Center of Excellence, said, “New treatment options that can slow disease progression are critical for people with ALS. This gives them more time for us to explore curative treatments.”

Every June 21st is World Gradual Freezing Day. On this occasion, WuXi AppTec will hold a special session on amyotrophic lateral sclerosis (ALS) and neuromuscular disease (NMD) in the “Let Science Lead” series of public welfare forums on rare diseases.

From multiple perspectives, such as medical needs, the current situation and cutting-edge models of new drug research and development, and the future blueprint for overcoming chronic diseases, we will jointly explore the road of innovation, and bring together cooperative forces to transform the disease management of ALS and NMD.

References:

[1] Amylyx Pharmaceuticals Announces Health Canada Approval of ALBRIOZA™ for the Treatment of ALS. Retrieved June 13, 2022, from https://www.amylyx.com/media/amylyx-pharmaceuticals-announces-health-canada-approval-of-albriozatm-for-the-treatment-of-als

[2] Amylyx Pharmaceuticals. Retrieved June 13, 2022, from https://investors.amylyx.com/static-files/8d7188f5-9c9e-4123-8204-e54fab324948

Original title: The first batch in the world! A century-old disease with a fatality rate of 100% ushered in innovative treatments

Canadian regulator approves Albrioza to launch innovative approach to ALS

(source:internet, reference only)

Disclaimer of medicaltrend.org